-
Gene Cradle and Byongen Therapeutics Partner on Next-Generation DMD Gene Therapies
•
Gene Cradle and Byongen Therapeutics, both Beijing-based gene therapy specialists, have formed a strategic alliance to develop next-generation gene therapies for Duchenne muscular dystrophy (DMD). Collaboration FocusGene Cradle, which initiated its DMD gene therapy project in 2021, has focused on optimizing Dystrophin proteins and regulatory elements. The company has designed…
-
Gene Cradle’s GC310 Receives Tacit Approval from NMPA for Wilson’s Disease
•
Beijing-based gene therapy specialist Gene Cradle announced that it has received tacit clinical approval from the National Medical Products Administration (NMPA) for its GC310, an adeno-associated virus (AAV) gene therapy for hepatolenticular degeneration, also known as Wilson’s disease. This approval marks a significant step forward in the development of a…
-
Gene Cradle Initiates First Regulatory Gene Therapy Study in China for Late-Onset Pompe Disease
•
Gene Cradle, a Beijing-based gene therapy specialist, has achieved a milestone by administering its GC301 to the first patient with late-onset Pompe disease (LOPD) in a regulatory study in China. This marks the nation’s first patient dosing of an adeno-associated virus (AAV) gene therapy for LOPD. GC301 is an innovative…
-
Beijing’s Gene Cradle Secures Pre-Series B+ Funding Led by Cash Capital
•
Gene Cradle, a Beijing-based gene therapy specialist, has reportedly secured tens of millions of renminbi in a pre-Series B+ financing round, with the investment being solely provided by Cash Capital. Company Background and PipelineFounded in 2018, Gene Cradle has established itself as a leader in the development and manufacturing of…
